Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Update

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) was the recipient of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 61,400 shares, a growth of 2,174.1% from the December 15th total of 2,700 shares. Based on an average daily volume of 26,100 shares, the short-interest ratio is presently 2.4 days. Currently, 0.7% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

Separately, Benchmark reaffirmed a “speculative buy” rating and issued a $8.00 price objective on shares of Anebulo Pharmaceuticals in a research report on Tuesday, November 19th.

Insider Activity

In other news, Director Aron R. English acquired 10,101,010 shares of Anebulo Pharmaceuticals stock in a transaction on Monday, December 23rd. The stock was acquired at an average cost of $0.99 per share, with a total value of $9,999,999.90. Following the transaction, the director now owns 15,467,300 shares of the company’s stock, valued at approximately $15,312,627. This trade represents a 188.23 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 85.90% of the company’s stock.

Anebulo Pharmaceuticals Price Performance

Shares of Anebulo Pharmaceuticals stock traded up $0.06 on Wednesday, reaching $1.66. 911 shares of the company traded hands, compared to its average volume of 18,735. Anebulo Pharmaceuticals has a 52 week low of $0.80 and a 52 week high of $3.30. The company has a 50 day moving average of $1.51 and a 200 day moving average of $1.86. The firm has a market capitalization of $43.05 million, a PE ratio of -5.53 and a beta of -1.14.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.